Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 483

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

Open access
Moayyedi, Paul, Eikelboom, John W., Bosch, Jackie, Connolly, Stuart J., Dyal, Leanne, Shestakovska, Olga, Leong, Darryl, Anand, Sonia S., Störk, Stefan, Branch, Kelley R.H., Bhatt, Deepak L., Verhamme, Peter B., O’Donnell, Martin, Maggioni, Aldo P., Lonn, Eva M., Piegas, Leopoldo S., Ertl, Georg, Keltai, Matyas, Bruns, Nancy Cook, Muehlhofer, Eva, Dagenais, Gilles R., Kim, Jae-Hyung, Hori, Masatsugu, Steg, P. Gabriel, Hart, Robert G., Diaz, Rafael, Alings, Marco, Widimsky, Petr, Avezum, Alvaro, Probstfield, Jeffrey, Zhu, Jun, Liang, Yan, Lopez-Jaramillo, Patricio, Kakkar, Ajay K., Parkhomenko, Alexander N., Ryden, Lars, Pogosova, Nana, Dans, Antonio L., Lanas, Fernando, Commerford, Patrick J., Torp-Pedersen, Christian, Guzik, Tomek J., Vinereanu, Dragos, Tonkin, Andrew M., Lewis, Basil S., Felix, Camilo, Yusoff, Khalid, Metsarinne, Kaj P., Fox, Keith A.A., Yusuf, Salim·2019·Gastroenterology

Abstract

BACKGROUND & AIMS Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies. We aimed to confirm these findings in an adequately powered randomized trial. METHODS We performed a 3x2 partial factorial double-blind trial of 17,598 participants with stable cardiovascular disease and peripheral artery disease randomly assigned to groups given pantoprazole (40 mg daily, n=8791) or placebo (n=8807). Participants were also randomly assigned to groups that received rivaroxaban (2.5 mg twice daily) with aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg) alone. We collected data on development of pneumonia, Clostridium difficile infection, other enteric infections, fractures, gastric atrophy, chronic kidney disease, diabetes, chronic obstructive lung disease, dementia, cardiovascular disease, cancer, hospitalizations, and all-cause mortality every 6 months. Patients were followed up for a median of 3.01 years, with 53,152 patient years of follow up. RESULTS There was no statistically significant difference between the pantoprazole and placebo groups in safety events except for enteric infections (1.4% vs 1.0% in the placebo group; odds ratio, 1.33; 95% CI, 1.01-1.75). For all other safety outcomes, proportions were similar between groups except for C difficile infection, which was approximately twice as common in the pantoprazole vs the placebo group, although there were only 13 events, so this difference was not statistically significant. CONCLUSIONS In a large placebo-controlled randomized trial, we found that pantoprazole is not associated with any adverse event when used for 3 years, with the possible exception of an increased risk of enteric infections. Clinicaltrials.gov identifier: NCT01776424 (https://clinicaltrials.gov/ct2/show/NCT01776424).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2019.05.056

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 483

Metadata

Authors
Moayyedi, P., Eikelboom, J. W., Bosch, J., Connolly, S. J., Dyal, L., Shestakovska, O., Leong, D., Anand, S. S., Störk, S., Branch, K. R. H., Bhatt, D. L., Verhamme, P. B., O’Donnell, M., Maggioni, A. P., Lonn, E. M., Piegas, L. S., Ertl, G., Keltai, M., Bruns, N. C., Muehlhofer, E., Dagenais, G. R., Kim, J.-H., Hori, M., Steg, P. G., Hart, R. G., Diaz, R., Alings, M., Widimsky, P., Avezum, A., Probstfield, J., Zhu, J., Liang, Y., Lopez-Jaramillo, P., Kakkar, A. K., Parkhomenko, A. N., Ryden, L., Pogosova, N., Dans, A. L., Lanas, F., Commerford, P. J., Torp-Pedersen, C., Guzik, T. J., Vinereanu, D., Tonkin, A. M., Lewis, B. S., Felix, C., Yusoff, K., Metsarinne, K. P., Fox, K. A. A., & Yusuf, S.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2019-09
Volume
157
Issue
3
Pages
682-691.e2
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2946868571
Cited by
483
References
35
FWCI
41.73
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. https://app.cochat.ai/papers/10.1053/j.gastro.2019.05.056
The paper
Moayyedi, P., Eikelboom, J. W., Bosch, J., Connolly, S. J., Dyal, L., Shestakovska, O., Leong, D., Anand, S. S., Störk, S., Branch, K. R. H., Bhatt, D. L., Verhamme, P. B., O’Donnell, M., Maggioni, A. P., Lonn, E. M., Piegas, L. S., Ertl, G., Keltai, M., Bruns, N. C., . . . Yusuf, S. (2019). Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.05.056

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.